Published mark
TEVA PHARMACEUTICAL INDUSTRIES LTD
NYSE: TEVA. Canonical company identity and public leadership record.
US
Record source reportedRecord not claimedNo Eval published
- Alpha ID
- alpha:company:1ab4e417-6727-4cb7-8135-8765fcabc050
- SEC CIK
- 0000818686
- Website
- www.tevapharm.com Open
- Record version
- vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 24, 2026
- Newest evidence
- May 28, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Richard FrancisPresident, Chief Executive Officer & Director
- Chair
- Sol J. Barer
- Independent
- 9 / 1010 directors published
- Published claims
- 534 distinct sources
- Evidence records
- 130 pinned
- Source conflicts
- 0None open
Built from 4 distinct sources and 13 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
CorroboratedSource reportedAlpha inferenceNot disclosed
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
DIRECTOR APPOINTED
Chen Lichtenstein seat on TEVA PHARMACEUTICAL INDUSTRIES LTD, effective 2024-01-01.
EffectiveEffective Jan 1, 2024E3
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| Senior VP & Chief Accounting Officer | Amir Weiss | Not captured | unknown | Source reportedE4 |
| Senior Vice President of Investor Relations & Competitive Intelligence | Christopher J. Stevo | Not captured | unknown | Source reportedE5 |
| Executive VP & Chief Legal Officer | David R. Mcavoy | Not captured | unknown | Source reportedE6 |
| Executive VP & CFO | Eliyahu Sharon Kalif | Not captured | unknown | Source reportedE7 |
| Executive Vice President of Global R&D and Chief Medical Officer | Eric A. Hughes | Not captured | unknown | Source reportedE8 |
| Senior Vice President, Global Compliance & Ethics Officer | Kathleen Veit | Not captured | unknown | Source reportedE9 |
| Executive Vice President of Global Operations | Matthew Shields | Not captured | unknown | Source reportedE10 |
| President, Chief Executive Officer & Director | Richard Francis | Not captured | unknown | Source reportedE11 |
| Executive Vice President of European Commercial | Richard Gordon Daniell | Not captured | unknown | Source reportedE12 |
Board of directors
Evidence10 directors published. 9 of 10 with a published determination are independent.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Amir Elstein | Independent | 2009 | AuditCorporate Governance and NominatingCorporate Governance and Nominating; Audit; Finance and InvestmentFinance and Investment | Source reportedE3 |
| Chen Lichtenstein | Independent | 2024 | AuditAudit; Compliance; Finance and InvestmentComplianceFinance and Investment | Source reportedE3 |
| Gerald Lieberman | Independent | 2015 | Audit, chairAudit · Chair; Human Resources and Compensation; Finance and InvestmentFinance and InvestmentHuman Resources and Compensation | Source reportedE3 |
| Perry D. Nisen | Independent | 2017 | ComplianceHuman Resources and CompensationScience and TechnologyScience and Technology; Compliance; Human Resources and Compensation | Source reportedE3 |
| Prof. Ronit Satchi-Fainaro | Independent | 2018 | ComplianceCompliance; Science and Technology; Corporate Governance and NominatingCorporate Governance and NominatingScience and Technology | Source reportedE2 |
| Richard Francis | Not independent | 2023 | None published | Source reportedE3 |
| Roberto Mignone | Independent | 2017 | AuditCorporate Governance and Nominating, chairCorporate Governance and Nominating · Chair; Finance and Investment; AuditFinance and Investment | Source reportedE3 |
| Rosemary A. Crane | Independent | 2015 | Human Resources and Compensation, chairHuman Resources and Compensation · Chair; Science and TechnologyScience and Technology | Source reportedE3 |
| Sol J. Barer | IndependentChair | 2015 | None published | Source reportedE2 |
| Tal Zaks | Independent | 2021 | None published | Source reportedE3 |
Committees and risk ownership
Evidence| Committee | Chair | Members | Risks assigned |
|---|---|---|---|
| Audit | Gerald Lieberman | Gerald Lieberman, Amir Elstein, Chen Lichtenstein, Roberto Mignone | Not described in the published record |
| Audit · Chair; Human Resources and Compensation; Finance and Investment | Not published | Gerald Lieberman | financial |
| Audit; Compliance; Finance and Investment | Not published | Chen Lichtenstein | regulatory, financial |
| Compliance | Not published | Chen Lichtenstein, Perry D. Nisen, Prof. Ronit Satchi-Fainaro | regulatory |
| Compliance; Science and Technology; Corporate Governance and Nominating | Not published | Prof. Ronit Satchi-Fainaro | regulatory |
| Corporate Governance and Nominating | Roberto Mignone | Roberto Mignone, Amir Elstein, Prof. Ronit Satchi-Fainaro | Not described in the published record |
| Corporate Governance and Nominating · Chair; Finance and Investment; Audit | Not published | Roberto Mignone | financial |
| Corporate Governance and Nominating; Audit; Finance and Investment | Not published | Amir Elstein | financial |
| Finance and Investment | Not published | Amir Elstein, Chen Lichtenstein, Gerald Lieberman, Roberto Mignone | financial |
| Human Resources and Compensation | Rosemary A. Crane | Rosemary A. Crane, Gerald Lieberman, Perry D. Nisen | Not described in the published record |
| Human Resources and Compensation · Chair; Science and Technology | Not published | Rosemary A. Crane | Not described in the published record |
| Science and Technology | Not published | Perry D. Nisen, Prof. Ronit Satchi-Fainaro, Rosemary A. Crane | Not described in the published record |
| Science and Technology; Compliance; Human Resources and Compensation | Not published | Perry D. Nisen | regulatory |
Committee RecordAudit: Chair Gerald Lieberman; Members Gerald Lieberman (Chair); Amir Elstein; Chen Lichtenstein; Roberto Mignone
Committee AppointmentGerald Lieberman: chair, Audit
Committee AppointmentAmir Elstein: member, Audit
Committee AppointmentChen Lichtenstein: member, Audit
Committee AppointmentRoberto Mignone: member, Audit
Committee RecordCompliance: Chair not stated; Members Chen Lichtenstein; Perry D. Nisen; Prof. Ronit Satchi-Fainaro
Committee AppointmentChen Lichtenstein: member, Compliance
Committee AppointmentPerry D. Nisen: member, Compliance
Committee AppointmentProf. Ronit Satchi-Fainaro: member, Compliance
Committee RecordCorporate Governance and Nominating: Chair Roberto Mignone; Members Roberto Mignone (Chair); Amir Elstein; Prof. Ronit Satchi-Fainaro
Committee AppointmentRoberto Mignone: chair, Corporate Governance and Nominating
Committee AppointmentAmir Elstein: member, Corporate Governance and Nominating
Committee AppointmentProf. Ronit Satchi-Fainaro: member, Corporate Governance and Nominating
Committee RecordFinance and Investment: Chair not stated; Members Amir Elstein; Chen Lichtenstein; Gerald Lieberman; Roberto Mignone
Committee AppointmentAmir Elstein: member, Finance and Investment
Committee AppointmentChen Lichtenstein: member, Finance and Investment
Committee AppointmentGerald Lieberman: member, Finance and Investment
Committee AppointmentRoberto Mignone: member, Finance and Investment
Committee RecordHuman Resources and Compensation: Chair Rosemary A. Crane; Members Rosemary A. Crane (Chair); Gerald Lieberman; Perry D. Nisen
Committee AppointmentRosemary A. Crane: chair, Human Resources and Compensation
Committee AppointmentGerald Lieberman: member, Human Resources and Compensation
Committee AppointmentPerry D. Nisen: member, Human Resources and Compensation
Committee RecordScience and Technology: Chair not stated; Members Perry D. Nisen; Prof. Ronit Satchi-Fainaro; Rosemary A. Crane
Committee AppointmentPerry D. Nisen: member, Science and Technology
Committee AppointmentProf. Ronit Satchi-Fainaro: member, Science and Technology
Committee AppointmentRosemary A. Crane: member, Science and Technology
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Principal executive officerRichard Francis, President, Chief Executive Officer & Director
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
Financials and market context
EvidenceSecurity ListingTEVA (NYSE)
Security ListingTEVA (TASE)
Security ListingTEVJF (OTC)
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 24, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.
Governance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Legal NameTEVA PHARMACEUTICAL INDUSTRIES LTD
Entity StatusPublic listing published
Published FactUS
Published FactIL
Published FactHealthcare
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Amir WeissSenior VP & Chief Accounting Officercompany:1ab4e417-6727-4cb7-8135-8765fcabc050:leadership_role:18
- Christopher J. StevoSenior Vice President of Investor Relations & Competitive Intelligencecompany:1ab4e417-6727-4cb7-8135-8765fcabc050:leadership_role:19
- David R. McavoyExecutive VP & Chief Legal Officercompany:1ab4e417-6727-4cb7-8135-8765fcabc050:leadership_role:20
- Eliyahu Sharon KalifExecutive VP & CFOcompany:1ab4e417-6727-4cb7-8135-8765fcabc050:leadership_role:21
- Eric A. HughesExecutive Vice President of Global R&D and Chief Medical Officercompany:1ab4e417-6727-4cb7-8135-8765fcabc050:leadership_role:22
- Kathleen VeitSenior Vice President, Global Compliance & Ethics Officercompany:1ab4e417-6727-4cb7-8135-8765fcabc050:leadership_role:23
- Matthew ShieldsExecutive Vice President of Global Operationscompany:1ab4e417-6727-4cb7-8135-8765fcabc050:leadership_role:24
- Richard FrancisPresident, Chief Executive Officer & Directorcompany:1ab4e417-6727-4cb7-8135-8765fcabc050:leadership_role:25, company:1ab4e417-6727-4cb7-8135-8765fcabc050:leadership_role:14
- Richard Gordon DaniellExecutive Vice President of European Commercialcompany:1ab4e417-6727-4cb7-8135-8765fcabc050:leadership_role:26
- Amir ElsteinDirectorcompany:1ab4e417-6727-4cb7-8135-8765fcabc050:leadership_role:9
- Chen LichtensteinDirectorcompany:1ab4e417-6727-4cb7-8135-8765fcabc050:leadership_role:10
- Gerald LiebermanDirectorcompany:1ab4e417-6727-4cb7-8135-8765fcabc050:leadership_role:11
- Perry D. NisenDirectorcompany:1ab4e417-6727-4cb7-8135-8765fcabc050:leadership_role:12
- Prof. Ronit Satchi-FainaroDirectorcompany:1ab4e417-6727-4cb7-8135-8765fcabc050:leadership_role:13
- Roberto MignoneDirectorcompany:1ab4e417-6727-4cb7-8135-8765fcabc050:leadership_role:15
- Rosemary A. CraneDirectorcompany:1ab4e417-6727-4cb7-8135-8765fcabc050:leadership_role:16
- Sol J. BarerChairman of the Boardcompany:1ab4e417-6727-4cb7-8135-8765fcabc050:leadership_role:8
- Tal ZaksDirectorcompany:1ab4e417-6727-4cb7-8135-8765fcabc050:leadership_role:17
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 13 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
Claiming not yet available
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 24, 2026. Cited by 8 Claims.
- E2sec proxy. Published Apr 16, 2024. Retrieved Sep 2, 2026. Cited by 2 Claims.
- E3sec def 14a. Published May 28, 2026. Retrieved Oct 20, 2026. Cited by 8 Claims.
- E4other. Published Apr 25, 2026. Retrieved Apr 25, 2026. Cited by 1 Claim.
- E5other. Published Apr 25, 2026. Retrieved Apr 25, 2026. Cited by 1 Claim.
- E6other. Published Apr 25, 2026. Retrieved Apr 25, 2026. Cited by 1 Claim.
- E7other. Published Apr 25, 2026. Retrieved Apr 25, 2026. Cited by 1 Claim.
- E8other. Published Apr 25, 2026. Retrieved Apr 25, 2026. Cited by 1 Claim.
- E9other. Published Apr 25, 2026. Retrieved Apr 25, 2026. Cited by 1 Claim.
- E10other. Published Apr 25, 2026. Retrieved Apr 25, 2026. Cited by 1 Claim.
- E11other. Published Apr 25, 2026. Retrieved Apr 25, 2026. Cited by 1 Claim.
- E12other. Published Apr 25, 2026. Retrieved Apr 25, 2026. Cited by 1 Claim.
- E13board_seats. sec def 14a. Cited by 26 Claims.
What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 24, 2026- Chen Lichtenstein seat on TEVA PHARMACEUTICAL INDUSTRIES LTD, effective 2024-01-01.
- Audit; Compliance; Finance and Investment committee of TEVA PHARMACEUTICAL INDUSTRIES LTD, effective 2024-01-01.
- Chen Lichtenstein member of Audit; Compliance; Finance and Investment, effective 2024-01-01.
- Richard Francis seat on TEVA PHARMACEUTICAL INDUSTRIES LTD, effective 2023-01-01.
- Tal Zaks seat on TEVA PHARMACEUTICAL INDUSTRIES LTD, effective 2021-01-01.
- Prof. Ronit Satchi-Fainaro seat on TEVA PHARMACEUTICAL INDUSTRIES LTD, effective 2018-01-01.
- Compliance; Science and Technology; Corporate Governance and Nominating committee of TEVA PHARMACEUTICAL INDUSTRIES LTD, effective 2018-01-01.
- Prof. Ronit Satchi-Fainaro member of Compliance; Science and Technology; Corporate Governance and Nominating, effective 2018-01-01.
- Perry D. Nisen seat on TEVA PHARMACEUTICAL INDUSTRIES LTD, effective 2017-01-01.
- Roberto Mignone seat on TEVA PHARMACEUTICAL INDUSTRIES LTD, effective 2017-01-01.
- Corporate Governance and Nominating · Chair; Finance and Investment; Audit committee of TEVA PHARMACEUTICAL INDUSTRIES LTD, effective 2017-01-01.
- Roberto Mignone member of Corporate Governance and Nominating · Chair; Finance and Investment; Audit, effective 2017-01-01.
- Science and Technology; Compliance; Human Resources and Compensation committee of TEVA PHARMACEUTICAL INDUSTRIES LTD, effective 2017-01-01.
- Perry D. Nisen member of Science and Technology; Compliance; Human Resources and Compensation, effective 2017-01-01.
- Gerald Lieberman seat on TEVA PHARMACEUTICAL INDUSTRIES LTD, effective 2015-01-01.
- Rosemary A. Crane seat on TEVA PHARMACEUTICAL INDUSTRIES LTD, effective 2015-01-01.
- Sol J. Barer seat on TEVA PHARMACEUTICAL INDUSTRIES LTD, effective 2015-01-01.
- Sol J. Barer chairs board TEVA PHARMACEUTICAL INDUSTRIES LTD, effective 2015-01-01.
- Audit · Chair; Human Resources and Compensation; Finance and Investment committee of TEVA PHARMACEUTICAL INDUSTRIES LTD, effective 2015-01-01.
- Gerald Lieberman member of Audit · Chair; Human Resources and Compensation; Finance and Investment, effective 2015-01-01.
- Human Resources and Compensation · Chair; Science and Technology committee of TEVA PHARMACEUTICAL INDUSTRIES LTD, effective 2015-01-01.
- Rosemary A. Crane member of Human Resources and Compensation · Chair; Science and Technology, effective 2015-01-01.
- Amir Elstein seat on TEVA PHARMACEUTICAL INDUSTRIES LTD, effective 2009-01-01.
- Corporate Governance and Nominating; Audit; Finance and Investment committee of TEVA PHARMACEUTICAL INDUSTRIES LTD, effective 2009-01-01.
- Amir Elstein member of Corporate Governance and Nominating; Audit; Finance and Investment, effective 2009-01-01.